[Clinical application of mesenchymal stem cells in treatment of acute-on-chronic liver failure and related research advances]

Zhonghua Gan Zang Bing Za Zhi. 2017 Sep 20;25(9):651-654. doi: 10.3760/cma.j.issn.1007-3418.2017.09.003.
[Article in Chinese]

Abstract

Acute-on-chronic liver failure is a syndrome characterized by acute exacerbation of chronic hepatitis, organ failure, and high mortality. Clinical treatment of acute-on-chronic liver failure included comprehensive medical treatment, artificial liver support system, and liver transplantation, but such methods have their own shortcomings and patients tend to have a poor prognosis. Mesenchymal stem cells (MSCs), as a new type of cell therapy, have wide sources and are easy to extract and culture. Many studies have shown that MSC treatment not only helps to achieve a high survival rate, but also has good tolerability and safety; therefore, the clinical value of MSCs has become a hot research topic. This article reviews the clinical studies on acute-on-chronic liver failure, related mechanisms, and research advances, in order to provide a reference for future clinical trials and application.

慢加急性肝衰竭以慢性肝炎急性加重、器官衰竭及病死率高为特点。临床治疗如内科综合治疗、人工肝支持系统、肝移植各自均存在不同程度的缺陷,总体预后不佳。间充质干细胞(MSCs)作为一种新型细胞治疗,来源广泛,且提取、培养方便,多项研究显示MSCs治疗不仅获得了较高生存率,并且具有良好的耐受性和安全性,成为临床应用研究的热点。现就当前MSCs应用于慢加急性肝衰竭的临床研究、相关机制及研究进展进行阐述,以期为未来开展临床试验及应用提供参考。.

Keywords: Acute-on-chronic liver failure; Cell transplantation; Mesenchymal stem cells.

Publication types

  • Review

MeSH terms

  • Acute-On-Chronic Liver Failure / therapy*
  • Humans
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology*